Financials in USD. Standardized financial statements.
A compact view of how CEN Biotech, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $987,112 | $626,867 | $0 | $0 | $0 | $0 | $2,321 | $0 | $0 | $0 |
| Revenue Growth? | +57.5% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $489,110 | $0 | $435,536 | $2.58M | $4.37M | $0 | $142,929 | $0 | $0 | $0 |
| Gross Profit? | $498,000 | $626,867 | -$435,536 | -$2.58M | -$4.37M | -$11.61M | -$141,000 | $0 | $0 | $0 |
| Gross Margin? | +50.5% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | -6075.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $1.76M | $19.66M | $1.77M | $2.58M | $3.10M | $11.61M | $1.04M | $1.17M | $3.01M | $570,718 |
| Operating Income? | -$1.26M | -$19.04M | -$2.21M | -$2.58M | -$3.10M | -$11.61M | -$1.19M | -$1.04M | -$3.01M | -$571,000 |
| EBITDA? | -$773,000 | -$17.63M | $18.36M | -$1.90M | -$4.22M | -$11.61M | -$6.49M | -$1.17M | -$150,000 | $0 |
| Income Before Tax | -$1.51M | -$18.94M | $14.25M | -$5.66M | -$7.53M | -$14.08M | -$7.58M | -$2.41M | -$3.16M | -$571,000 |
| Income Tax Expense | $0 | -$36,356 | $0 | $0 | -$289,000 | $0 | $1.60M | $0 | $0 | $0 |
| Net Income? | -$1.51M | -$18.90M | $14.25M | -$5.66M | -$7.53M | -$14.08M | -$7.58M | -$2.41M | -$3.16M | -$571,000 |
| EPS? | $-0.02 | $-0.45 | $0.52 | $-0.35 | $-0.30 | $-1.68 | $-0.92 | $-0.34 | $-0.45 | $-0.08 |
| Diluted EPS? | $-0.02 | $-0.45 | $0.45 | $-0.35 | $-0.30 | $-1.68 | $-0.92 | $-0.34 | $-0.45 | $-0.08 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality